News

Video | Q&A with Paul Kase, SVP, Commercial Operations

12 July 2024
In this Q&A with Paul Kase, Lumos’ SVP, Commercial Operations, Paul outlines how Lumos is working in partnership with Henry Schein to access key global markets, and the imminent availability of FebriDx® to Australian healthcare practitioners as Australia enters its peak flu season.

Take a look:

Related news
Lumos Diagnostics receives CPT PLA procedure code approval for FebriDx™ in the US
5 December 2024
Nine News Coverage
21 November 2024

Inquire now

We are inviting qualified B2B Service inquiries for those seeking to develop point-of-care reader technology

By entering your email address you are agreeing to our Privacy Policy.

Innovation at the point-of-care

2024 Lumos Diagnostics

Quick links
Engage with us